Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Primary Results of the Short Term (6 month) Cohort

Purpose: To study the safety and effectiveness of the HeartMate 3 (HM3) Left Ventricular Assist System (LVAS).

Trial Design: Prospective, randomized 1:1, controlled trial comparing the HM3 to HMII for non-inferiority. Patients have advanced HF and are LVAS candidates. Evaluations at 6 months and 2 years.

Primary Endpoint: Composite at 6 months (survival to transplant, recovery, or LVAD support free of debilitating stroke or reoperation to replace the pump).

Trial Results	HeartMate II	HeartMate 3	P value non-inferiority
Composite Endpoint	76.8%	86.2%	<0.0001

Conclusions: The composite outcome was improved at 6 months with HM3 in this trial compared to HMII.

Presented by: Mandeep R Mehra, Scientific Sessions 2016, New Orleans, LA, USA